Latest Asx Filings News

Riversgold has dramatically expanded its Kalgoorlie Gold Project tenements by over 800%, positioning itself for long-term development with a new mining agreement that shares funding and profits with MEGA Resources.

Pentanet Limited has reported a solid half-year performance for the period ending 31 December 2025, with revenue growth and a significant surge in EBITDA, while narrowing its net loss. Both its Telecommunications and Gaming segments contributed to the improved results, supported by subscriber growth and operational efficiencies.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

betr Entertainment has extended its NAB facility agreement maturity to July 2027, reinforcing its financial flexibility and growth ambitions. This move underscores a strong partnership with NAB amid betr’s evolving wagering business.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Piche Resources announces the resignation of Managing Director Karilyn Farmer effective April 2026, with seasoned geologist Claudio Devaux appointed as country manager to ensure continuity in exploration activities.

Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.

Acorn Capital Investment Fund Limited has reported a remarkable half-year performance for the period ending 31 December 2025, with revenue and profit soaring over 300%. The fund also declared a fully franked interim dividend of 3.5 cents per share, signalling confidence in its investment strategy.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Dominion Income Trust 1 has reported a robust $12.3 million profit and paid distributions totaling 359.41 cents per unit in its inaugural half-year ending December 2025. The Trust outperformed its benchmark, signalling a promising start for investors.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.